✓
Full-Scale Clinical Trial Management
Expertise in Phase III and Phase IV interventional trials.
VCRC · Est. 2001
VACSERA Clinical Research Center
A regional hub for high-impact vaccine trials and global health partnerships.
GCP 100% ComplianceEDA · IRB · CRE RegisteredPhase III & IVWHO Partner
An Integrated Clinical Research Ecosystem
VCRC is the specialized research arm of VACSERA — the oldest vaccine producer in the Middle East. Established in 2001 with a skilled, experienced team capable of conducting clinical studies in full compliance with regulatory and quality standards. Located in Dokki, Giza for easy patient access.
Strategic Objective
To enable high-impact clinical research in Egypt by:
- ▸Streamline drug development
- ▸Improve patient access to advanced care
- ▸Build regional capacity for multinational trials
- ▸Integrate stakeholders into a unified ecosystem
Physical Infrastructure
●
Dedicated patient examination clinics
●
Research pharmacy with temperature control & security
●
On-site laboratory services
●
Centrifuge and full lab equipment
●
Vital-signs monitoring equipment
●
Contracted ICU services
●
Secure document archiving
●
Private offices for staff & monitors
●
Integrated Electronic Health Records
Core Competencies & Services
A comprehensive suite of services for international vaccine developers and global health organizations.
✓
Mega-Trial Execution
Proven capacity to recruit hundreds of participants simultaneously.
✓
Regulatory & Ethical Navigation
Streamlined EDA approvals and IRB / Supreme Council coordination.
✓
Cold Chain Logistics
On-site storage at 2–8°C, −20°C and −80°C with full validation.
✓
Pharmacovigilance & Safety Reporting
Continuous monitoring with international safety standards.
✓
Bioequivalence Services
End-to-end BE study design and execution.
Therapeutic Areas
VaccinesAllergy & ImmunologyDiabetesHematologyCardiology
Lead investigators maintain a 100% GCP compliance rate, supported by a robust recruitment infrastructure that consistently delivers high-quality data and meets enrolment milestones ahead of schedule.
Leadership Team
G
Dr. Dalia Gad
Executive Director
B
Dr. Asmaa Abo Bakr
Quality Assurance
S
Dr. A. Shoukry
Regulatory Affairs
Access to Patient Population
Additional VACSERA capabilities supporting recruitment across multiple facilities.
25+
VACSERA Vaccination Center
branches across 7 governorates
16,000+
Blood Issuing & Transfusion Center
patients annually
6,000+
VACSERA Diabetes Center
patients annually
—
VACSERA Kidney Center
Specialized renal care
—
Allergy & Immunology Center
Therapeutic-area expertise
30
VACSERA National Heart Center
bed cardiovascular capacity
7
Medical Center Polyclinics
specialties incl. ophthalmology, dentistry, pediatrics
2
WHO Reference Laboratories
Polio RRL & National Influenza Centre
Center Achievements
2007
Human Albumin safety & efficacy in cirrhotic patients with tense ascites
—
TT vs Td immunization in pregnant women — randomized controlled trial (with NODCAR, MoHP, US NAMRU)
—
Polyvalent anti-snake & anti-scorpion serum post-marketing study (Ain Shams University Poison Control Center)
—
Sequential & combined immunization: Oral and Inactivated Polio Vaccines — controlled trial
—
ABEVAC — Phase II study on degenerative osteoarthritis (Chungbuk National University, Korea)
2021
Principal site for Egypt's first Phase III COVID-19 mega-trial (1,500+ participants)
International Studies & Collaborations
MADAUS GmbH, Cologne, Germany
Multicentre, double-blind, randomized Phase II/III silymarin study
WHO POL, Geneva
Poliovirus surveillance studies
WHO EMRO, Cairo
Survey of poliovirus antibodies during final stage of polio eradication
SINOVAC / China
Phase III clinical trial for inactivated COVID-19 vaccine (2020–2021)
Certification & Licenses
Registered with the Supreme Council of Research Ethics (CRE) in August 2025 per required guidelines, with active IRB registration.
Contact VCRC
- Address
- 51 Wezaret El Zeraa St., Agouza, Giza, Egypt
- Telephone
- 02 3761 1111 — ext 1060
- Fax
- 3339 6872
- Hotline
- 15292